Hilal KORKMAZ
(Gazi Üniversitesi, Tıp Fakültesi, Fizyoloji Anabilim Dalı, Ankara, Türkiye)
Mustafa AKŞAR
(Sağlık Bilimleri Üniversitesi, Etlik Zübeyde Hanım Kadın Sağlığı Eğitim ve Araştırma Hastanesi, Jinekolojik Onkoloji Anabilim Dalı, Ankara, Türkiye)
Halis Doğukan ÖZKAN
(Sağlık Bilimleri Üniversitesi, Etlik Zübeyde Hanım Kadın Sağlığı Eğitim ve Araştırma Hastanesi, Jinekolojik Onkoloji Anabilim Dalı, Ankara, Türkiye)
Vakkas KORKMAZ
(Sağlık Bilimleri Üniversitesi, Etlik Zübeyde Hanım Kadın Sağlığı Eğitim ve Araştırma Hastanesi, Jinekolojik Onkoloji Anabilim Dalı, Ankara, Türkiye)
Nurettin BORAN
(Sağlık Bilimleri Üniversitesi, Etlik Zübeyde Hanım Kadın Sağlığı Eğitim ve Araştırma Hastanesi, Jinekolojik Onkoloji Anabilim Dalı, Ankara, Türkiye)
Yıl: 2021Cilt: 54Sayı: 2ISSN: 0304-596X / 2148-7669Sayfa Aralığı: 217 - 223İngilizce

1 0
Predictive Value of Complete Blood Count Inflammatory Parameters for Epithelial Ovarian Cancers in Women During Reproductive Period
Background: Comparison of predictive values of complete blood count inflammatory parameters and serum CA-125 levels in the differential diagnosis of patients with epithelial ovarian tumor (EOTs) diagnosed in the reproductive period. Materials: In this study, 105 women patients in the reproductive period were retrospectively analyzed. The patients included were examined in terms of clinical, laboratory and pathological features. Results: The mean age of the patients was 41.5 ± 8.6 years and BMI was 28.6 ± 5.8 kg/m2. Of the whole study population, 54 (51.5%) were benign EOTs, 18 (17.1%) were borderline EOTs and 33 (31.4%) were malignant EOTs. When comparing these three tumor groups, a significant difference was found in terms of serum CA-125 [14.7 U/mL (2.7-238.6) vs 60.2 U/mL (7.8 – 557) vs 416.5 U/mL (2.4-7695), p<0.001, respectively], platelet count [294 x103/ μL (133-744) vs 303, x103/ μL (160-468) vs 383 x103/ μL (128-725), p = 0.018, respectively], neutrophil count [4.2, x103/ μL (1.9 -8.9) vs 4.9 x103/ μL (2.6- 10.9) vs 5.1 x103/ μL (2.2 – 10.7), p = 0.012], neutrophil-to-lymphocyte ratio (NLR) [2.1 (0.1-8.2) vs 2.6 (1.2 – 5.9) vs 3.1 (1-6.8), p = 0.021, respectively] and platelet-to-lymphocyte ratio (PLR) [154.4 (82.1-658.4) vs 168.1 (91.1-377.8) vs 201.5 (29.6-499.2), p = 0.008, respectively] values. In the ROC analyses, serum CA-125 levels (AUC= 0.818, p <0.001), platelet count (AUC= 0.673, p = 0.005) and PLR (AUC= 0.690, p = 0.002) values significantly predicted malignant EOTs. Conclusion: Preoperative platelet count, neutrophil count and PLR predict epithelial ovarian cancers significantly. However, diagnostic predictive values of all three parameters are lower than CA-125. Therefore, CA-125 is still the most valuable serum biochemical marker that can be used in the preoperative differential diagnosis of EOTs.
DergiAraştırma MakalesiErişime Açık
  • 1. Cannistra SA. Cancer of the ovary. The New England journal of medicine. 2004;351(24):2519-29.
  • 2. Munro AJ. Interpretation of EUROCARE-5. The Lancet Oncology. 2014;15(1):2-3.
  • 3. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet (London, England). 2019; 393(10177):1240-53.
  • 4. Chen L, Wang X, Shu J, Xu S, Wu Q, Yu Y. Diagnostic value of serum D-dimer, CA125, and neutrophil-to-lymphocyte ratio in differentiating ovarian cancer and endometriosis. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2019;147(2):212-8.
  • 5. Thomassin-Naggara I, Daraï E, Lécuru F, Fournier L. [Diagnostic value of imaging (ultrasonography, doppler, CT, MR, PET-CT) for the diagnosis of a suspicious ovarian mass and staging of ovarian, tubal or primary peritoneal cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]. Gynecologie, obstetrique, fertilite & senologie. 2019; 47(2):123-33.
  • 6. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer immunology, immunotherapy: CII. 2009; 58(1):15-23.
  • 7. Eltabbakh GH, Belinson JL, Kennedy AW, Gupta M, Webster K, Blumenson LE. Serum CA-125 measurements > 65 U/mL. Clinical value. The Journal of reproductive medicine. 1997; 42(10):617-24.
  • 8. Celkan TT. What does a hemogram say to us? Turk Pediatri Ars. 2020;55(2):103-16.
  • 9. Wu YY, Qin YY, Qin JQ, Zhang X, Lin FQ. Diagnostic value of derived neutrophil-to-lymphocyte ratio in patients with ovarian cancer. J Clin Lab Anal. 2019; 33(4): e22833.
  • 10. Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Annals of African medicine. 2019; 18(3):121-6.
  • 11. Kokcu A, Kurtoglu E, Celik H, Tosun M, Malatyalıoglu E, Ozdemir AZ. May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer? Asian Pacific journal of cancer prevention: APJCP. 2014;15(22):9781-4.
  • 12. Hernandez E, Donohue KA, Anderson LL, Heller PB, Stehman FB. The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology. 2000;78(2):137-42.
  • 13. Tamussino KF, Gücer F, Reich O, Moser F, Petru E, Scholz HS. Pretreatment hemoglobin, platelet count, and prognosis in endometrial carcinoma. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2001;11(3):236-40.
  • 14. Kuyumcuoglu U, Guzel AI, Celik Y, Erdemoğlu M. The association of preoperative thrombocytosis with prognostic factors in malign ovarian tumor. European journal of gynaecological oncology. 2010; 31(5): 514-6.
  • 15. Yilmaz E, Coskun EI, Sahin N, Ciplak B, Ekici K. MPV, NLR, and platelet count: new hematologic markers in diagnosis of malignant ovarian tumor. European journal of gynaecological oncology. 2017; 38(3): 346-9.
  • 16. Watrowski R, Heinze G, Jäger C, Forster J, Zeillinger R. Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016; 37(9): 12079-87.
  • 17. Yildirim M, Demir Cendek B, Filiz Avsar A. Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-tolymphocyte and platelet-to-lymphocyte ratios. Molecular and clinical oncology. 2015; 3(2):317-21.
  • 18. Bakacak M, Serin S, Ercan Ö, Köstü B, Bostancı MS, Bakacak Z, et al. Utility of preoperative neutrophilto- lymphocyte and platelet-to-lymphocyte ratios to distinguish malignant from benign ovarian masses. Journal of the Turkish German Gynecological Association. 2016;17(1):21-5.
  • 19. Yildirim MA, Seckin KD, Togrul C, Baser E, Karsli MF, Gungor T, et al. Roles of neutrophil/lymphocyte and platelet/lymphocyte ratios in the early diagnosis of malignant ovarian masses. Asian Pacific journal of cancer prevention: APJCP. 2014;15(16):6881-5.
  • 20. Prodromidou A, Andreakos P, Kazakos C, Vlachos DE, Perrea D, Pergialiotis V. The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer. Inflammation research: official journal of the European Histamine Research Society. 2017; 66(6): 467-75.
  • 21. Eo WK, Kim KH, Park EJ, Kim HY, Kim HB, Koh SB, et al. Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses. J Cancer. 2018;9(7):1165-72.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.